BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt307PMID 24131965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrated Genomic Analyses of Ovarian Carcinoma

  2011influential reference
• Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

  2011cited by this paper
• EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors.

  2011cited by this paper
• Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

  2008cited by this paper
• Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma

  2007cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007influential reference
• Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

  2006cited by this paper
• Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005influential reference
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

  2004cited by this paper
• Hereditary ovarian cancer in Poland.

  2004cited by this paper
• Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

  2004cited by this paper
• One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

  2004cited by this paper
• The PARP superfamily

  2004cited by this paper
• The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers

  2003cited by this paper
• Breast and ovarian cancer.

  2003cited by this paper
• Cancer incidence in BRCA1 mutation carriers

  2003cited by this paper
• Spatial and Temporal Cellular Responses to Single-Strand Breaks in Human Cells

  2003influential reference
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

  2003cited by this paper
• XRCC1 and DNA strand break repair.

  2003influential reference
• Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

  2003cited by this paper
• Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

  2003cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002influential reference
• Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

  2002cited by this paper
• Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

  2002cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

  2002cited by this paper
• Enhanced polyadenosine diphosphate‐ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma

  2001cited by this paper
• DNA double-strand breaks: signaling, repair and the cancer connection

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Distinct functions of BRCA1 and BRCA2 in double-strand break repair

  2001influential reference
• BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations

  2001cited by this paper
• A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage

  2001cited by this paper
• Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity

  2001cited by this paper
• Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

  2000influential reference
• Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.

  2000cited by this paper
• Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

  2000cited by this paper
• BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.

  2000cited by this paper
• Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.

  1999cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Involvement of poly(ADP-ribose) polymerase in base excision repair.

  1999cited by this paper
• Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

  1999cited by this paper
• Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.

  1998cited by this paper
• Involvement of the mismatch repair system in temozolomide-induced apoptosis.

  1998cited by this paper
• Brca2 is required for embryonic cellular proliferation in the mouse.

  1997cited by this paper
• RAD51 Interacts with the Evolutionarily Conserved BRC Motifs in the Human Breast Cancer Susceptibility Gene brca2 *

  1997influential reference
• Identification of the breast cancer susceptibility gene BRCA2

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• Proportion of breast cancer cases in the United States explained by well-established risk factors.

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Poly(ADP-ribose) polymerase: a molecular nick-sensor.

  1994cited by this paper
• Enhanced expression of poly(ADP‐ribose) synthetase gene in malignant lymphoma

  1991cited by this paper
• Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.

  1983cited by this paper
• Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure.

  1982cited by this paper
• ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells.

  1980cited by this paper

• Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities

  2025cites this paper
• Mut-Map: Comprehensive Computational Pipeline for Structural Mapping and Analysis of Cancer-Associated Mutations

  2024cites this paper
• Screening in Women With BRCA Mutations Revisited.

  2024cites this paper
• Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer

  2022cites this paper
• OTT_A_369844 815..826

  2022cites this paper
• Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer

  2022cites this paper
• Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants

  2022cites this paper
• New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment

  2022cites this paper
• Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

  2021cites this paper
• Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting

  2021cites this paper
• Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.

  2020cites this paper
• PARP inhibitors in the treatment of ovarian cancer

  2020cites this paper
• Patient Selection Biomarker Strategies for PARP Inhibitor Therapy.

  2020cites this paper
• Characterization of BRCA1/2-Directed ceRNA Network Identifies a Novel Three-lncRNA Signature to Predict Prognosis and Chemo-Response in Ovarian Cancer Patients With Wild-Type BRCA1/2

  2020cites this paper
• OTT_A_184971 5177..5187

  2019cites this paper
• The multi-factorial nature of clinical multidrug resistance in cancer.

  2019cites this paper
• Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy

  2019cites this paper
• DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes

  2019cites this paper
• Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer

  2019cites this paper
• Evidence to date: talazoparib in the treatment of breast cancer

  2019cites this paper
• Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer

  2019cites this paper
• LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.

  2019cites this paper
• Cyclophosphamide in Ovarian Cancer Subtypes: Time for a Comeback

  2018cites this paper
• Factors influencing risk‐based care of the childhood cancer survivor in the 21st century

  2018cites this paper
• Multi‐omics in high‐grade serous ovarian cancer: Biomarkers from genome to the immunome

  2018cites this paper
• High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

  2018cites this paper
• Mixed Malarial Infection with Pancytopenia in a Child with Acute Lymphoblastic Leukemia: An Unusual Presentation

  2018cites this paper
• Nitric Oxide and Platinum-Derivative-Based Regimens for Cancer Treatment: From Preclinical Studies to Clinical Trials

  2017cites this paper
• Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination.

  2017cites this paper
• Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

  2017cites this paper
• Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.

  2017cites this paper
• Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

  2017cites this paper
• Advances and Perspectives in the Treatment of High-Grade Serous Ovarian Cancer

  2017cites this paper
• Cancer‐derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism‐dependent targeting

  2017cites this paper
• Cytotoxic and targeted therapy for hereditary cancers

  2016cites this paper
• Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation

  2016cites this paper
• Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.

  2016cites this paper
• Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

  2016cites this paper
• Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.

  2016cites this paper
• PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.

  2016cites this paper
• Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target

  2016cites this paper
• New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors

  2016cites this paper
• Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples

  2016cites this paper
• Epithelial Ovarian Cancer, Low Malignant Potential, and Sex Cord Stromal Tumors of the Ovary

  2015cites this paper
• Current state of biomarkers in ovarian cancer prognosis.

  2015cites this paper
• New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.

  2015cites this paper
• Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells

  2015cites this paper
• Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis

  2014cites this paper
• Cell and molecular response to IORT treatment

  2014cites this paper
• PARP inhibition and synthetic lethality in ovarian cancer

  2014influential citation